Pharmaceutical Executive July 9, 2025
Justin Kozak discusses how the impact on medical breakthroughs and startups.
The White House’s plans to make significant cuts to funding from NIH is expected to have significant impact on the pharma industry for years to come. Justin Kozak, an executive VP at Founder Shield, spoke with Pharmaceutical Executive about the specific issues the industry might see as a result of these cuts.
What impact will cuts to funding from NIH have on pharma?
Pharmaceutical Executive: What impact will NIH cuts have for major medical breakthroughs and biotech progress?
Justin Kozak:The short answer is that the NIH cuts will significantly impede major medical breakthroughs and biotech progress. Billions less for early-stage research and clinical trials mean project delays or outright...
Today's Sponsors
Today's Sponsor